Encouraging Rigosertib Data Presented at EADV as Late Breake

Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet needNEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract studying rigosertib in patients with recessive dystrophic epidermolysis bullosa (R

Related Keywords

Salzburg , Austria , Berlin , Germany , Bruce Mackle , Johann Bauer , Steven Fruchtman , Mark Guerin , Nasdaq , Onconova Therapeutics Inc , European Academy Of Dermatology , Lifesci Advisors , Securities Exchange , Company Contact , University Hospital Salzburg , Late Breaking News , European Academy , Recessive Dystrophic Epidermolysis Bullosa , Metastatic Squamous Cell Carcinoma , Onconova Therapeutics , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Annual Report , Sci Advisors , Squamous Cell Carcinoma , Nc , Adv , Deb , Iopharmaceutical Company , Onconova , Patient ,